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Abstract: Background: Granuloma annulare is a chronic noninfectious granulomatous skin condition
with variable clinical presentations. Generalized granuloma annulare, defined as widespread disease with
>10 skin lesions, accounts for 15% of all cases. Numerous associated diseases have been controversially
discussed, most importantly diabetes mellitus, dyslipidemia, thyroid disease, malignancy and systemic
infections. Objectives: The objective of our study is to describe disease characteristics, treatment out-
come and associated diseases in patients treated at the Department of Dermatology of the University
Hospital Zurich during the last 20 years. Methods: The hospital database was searched for patients with
generalized granuloma annulare in the last 20 years (January 1, 1998, to December 31, 2017). Overall,
61 patients, 14 males and 47 females, were included in our study. The mean age was 58 years at first
consultation. The diagnosis was verified clinically and histologically. Results: Generalized granuloma
annulare occurred at a mean age of 55 years, more commonly in females. Pruritus was absent in 51% of all
patients. Metabolic diseases including diabetes mellitus, hypercholesterinemia and hypertriglyceridemia
were present in 10.5, 8.2 and 4.9%, respectively. Thyroid disease was present in 9.8% and malignant
disease in 23%, including colorectal cancer, lymphoproliferative disease, squamous cell carcinoma of the
esophagus, basal cell carcinoma and gynecological malignancy. Therapy was initiated in 92%, while
second- and third-line therapy was performed in 70 and 39%, respectively. Benefit during therapy (e.g.,
full and partial remission) was achieved in 39.3% during first-line, in 39.4% during second-line and in
33.8% during third-line treatment. Topical corticosteroids were the most commonly prescribed treat-
ment, mostly leading to stable disease (46.6%). Combined full and partial remission occurred in a large
proportion of patients receiving UVA1 (45%), PUVA (63.6%) and intralesional triamcinolone acetonide
(100%). Conclusions: Generalized granuloma annulare is a mostly asymptomatic and benign disease with
a strong tendency for treatment resistance. We suggest to screen all patients for dyslipidemia, thyroid
disease and malignant disease. While randomized trials are needed, we suggest topical corticosteroids as
the first-line treatment, intralesional triamcinolone acetonide for persistent solitary lesions and, if further
treatment is needed, UVA1 or PUVA.
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Abstract
Background: Granuloma annulare is a chronic noninfectious 
granulomatous skin condition with variable clinical presenta-
tions. Generalized granuloma annulare, defined as wide-
spread disease with > 10 skin lesions, accounts for 15% of all 
cases. Numerous associated diseases have been controver-
sially discussed, most importantly diabetes mellitus, dyslipid-
emia, thyroid disease, malignancy and systemic infections. 
Objectives: The objective of our study is to describe disease 
characteristics, treatment outcome and associated diseases 
in patients treated at the Department of Dermatology of the 
University Hospital Zurich during the last 20 years. Methods: 
The hospital database was searched for patients with gener-
alized granuloma annulare in the last 20 years (January 1, 
1998, to December 31, 2017). Overall, 61 patients, 14 males 
and 47 females, were included in our study. The mean age 
was 58 years at first consultation. The diagnosis was verified 
clinically and histologically. Results: Generalized granuloma 
annulare occurred at a mean age of 55 years, more common-
ly in females. Pruritus was absent in 51% of all patients. Meta-
bolic diseases including diabetes mellitus, hypercholesterin-
emia and hypertriglyceridemia were present in 10.5, 8.2 and 
4.9%, respectively. Thyroid disease was present in 9.8% and 
malignant disease in 23%, including colorectal cancer, lym-
phoproliferative disease, squamous cell carcinoma of the 
esophagus, basal cell carcinoma and gynecological malig-
nancy. Therapy was initiated in 92%, while second- and third-
line therapy was performed in 70 and 39%, respectively. Ben-
efit during therapy (e.g., full and partial remission) was 
achieved in 39.3% during first-line, in 39.4% during second-
line and in 33.8% during third-line treatment. Topical cortico-
steroids were the most commonly prescribed treatment, 
mostly leading to stable disease (46.6%). Combined full and 
partial remission occurred in a large proportion of patients 
receiving UVA1 (45%), PUVA (63.6%) and intralesional triam-
cinolone acetonide (100%). Conclusions: Generalized granu-
loma annulare is a mostly asymptomatic and benign disease 
with a strong tendency for treatment resistance. We suggest 
to screen all patients for dyslipidemia, thyroid disease and 
malignant disease. While randomized trials are needed, we 
suggest topical corticosteroids as the first-line treatment, in-
tralesional triamcinolone acetonide for persistent solitary le-
sions and, if further treatment is needed, UVA1 or PUVA. 
© 2020 The Author(s)
Published by S. Karger AG, Basel
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-




Granuloma annulare (GA) is a noninfectious, granu-
lomatous skin condition with variable clinical presenta-
tion [1]. Localized GA (LGA) is the most common form, 
presenting as erythematous, nonscaling, annular plaque 
mostly on distal extremities. Generalized GA (GGA) is 
defined as widespread disease with >  10 skin lesions and 
accounts for 15% of all cases, typically presenting with 
widespread annular and erythematous plaques on the 
trunk and, in smaller amounts, the extremities [2]. 
While LGA is usually self-limiting within 2 years, GGA 
and atypical GA disease may persist for several years 
with a tendency for treatment resistance [3]. In a retro-
spective analysis of patients suffering from GGA, 25% 
had disease persistence after 5 years and 10% after 10 
years [4]. Mixed lymphocytic and histiocytic infiltra-
tions have led to the hypothesis of a delayed-type hyper-
sensitivity reaction. Up until today, the etiology of GA 
remains unclear. Numerous diseases have been contro-
versially discussed to be associated with GGA, most im-
portantly diabetes mellitus, dyslipidemia, thyroid dis-
ease, malignancy and infections such as human immu-
nodeficiency virus [2]. In addition, certain medications 
have been associated with the onset of GA [5–7]. Given 
the controversial and only limited scientific data de-
rived from retrospective analysis, a consensus on diag-
nostic procedures upon diagnosis of LGA and GGA 
does not exist. Evidence-based therapy is scarce and re-
lies on case reports, case series and retrospective studies 
[3, 8]. When necessary, high-potency topical or intral-
esional corticosteroids are considered first-line thera-
peutic options [2]. Alternatives include topical calci-
neurin inhibitors, cryosurgery, laser and light therapy, 
amongst others [9–11]. No randomized controlled tri-
als evaluating different therapeutic regimens exist. The 
objective of our study is to describe disease characteris-
tics, treatment outcome and associated diseases in all 
patients treated for GGA at the Department of Derma-
tology of the University Hospital Zurich during the last 
20 years. 
Methods




Of 61 patients, 77% (n = 47) were female and 23% 
(n = 14) male. The mean age at time of first visit in our 
clinic was 58 years (58.57 ± 14.62 years). The most com-
mon skin types were 2 and 3. 85% (n = 52) of all patients 
were Caucasians (Table 1).
Search in the hospital information
system for patients with generalized
granuloma annulare from 1998 to 2017
(n = 61)
Analysis of data (n = 61)
 Exclusion of patients under 18 years
 according to ethical commission (n = 0)
 Exclusion of patients with no follow-up
 visits (n = 0)

































Fig. 1. Flowchart of the Methods: inclu-
sion.





Reported disease onset occurred at a mean age of 55 
years (55.64 ± 15.97 years), with a diagnostic delay of 
21.39 ± 30.8 months. The mean age at time of diagnosis 
was 58 years (58.12 ± 14.65 years). Pruritus was absent in 
51% (n = 31) of all patients, while mild to intermediate 
pruritus was present in 23% (n = 14) and severe pruritus 
in 7% (n = 4) of all patients. In 19% no data could be re-
trieved (Table 2). 
Treatment Outcome
Therapy was initiated in the majority of patients (n = 56, 
92%). Second line-therapy was pursued in 70% (n = 43) 
and third-line therapy in 39% (n = 24). Of all patients re-
ceiving first-line therapy, full remission was achieved in 
12.5% (n = 7) and partial remission in 26.8% (n = 15). Sta-
ble disease was seen in the majority of patients receiving 
first-line treatment (42.9%, n = 24) and only a minority had 
disease progression (12.5%, n = 7). Second-line treatment 
led to full remission in 11.6% (n = 5) while 27.9% showed 
partial remission (n = 12). Stable disease was achieved in 
most patients under second-line treatment (41.9%, n = 18), 
and only a minority had disease progression (12.5%, n = 
12). In patients receiving third-line treatment, 20.8% (n = 
5) achieved full remission, while only a minority had par-
tial remission (12.5%, n = 3). Most patients had stable dis-
ease (33.3%, n = 8), and only 1 patient (4.1%) progressed 
during third-line treatment (Fig. 2a).
Topical corticosteroids were the most commonly pre-
scribed treatment modality, followed by UVA1, potassi-
um iodatum, PUVA, UVB, intralesional triamcinolone 
acetonide and plaquenil. Topical steroids led to stable dis-
ease in most cases (46.6%, n = 27), and partial remission 
was achieved in 19% (n = 11). While full remission oc-
curred in only 6 patients (10.3%), disease progression was 
observed in 5 patients receiving topical steroids (8.6%). 
UVA1 led to full remission in 3 patients (15.0%), and 
most patients achieved partial remission (n = 6, 30%) or 
stable disease (n = 7, 35%). Only 1 patient had disease 
progression upon UVA1 (5.0%). Potassium iodatum 
treatment did not lead to full remission, while 25.0% 
showed partial remission (n = 3). Stable disease or disease 
progression occurred in 2 patients each (16.7%) during 
potassium iodatum treatment. In patients receiving 
PUVA, 3 patients had full remission (27.3%), while 4 pa-
tients showed partial remission (36.4%) and 3 stable dis-
ease (27.3%). Only 1 patient experienced disease progres-
sion (9.1%) during PUVA treatment. No patient receiv-
ing UVB treatment achieved full remission, while 37.5% 
(n = 3) showed partial remission and 50% (n = 4) stable 
disease. Only 1 patient had disease progression (12.5%) 
after UVB treatment. In patients treated with intralesion-
al triamcinolone acetonide, 60.0% (n = 3) had full remis-
sion and 40.0% (n = 2) partial remission, while no patients 
had disease progression. No patient taking Plaquenil ex-
perienced disease progression, while 1 patient achieved 
full remission (20.0%), 2 patients showed partial remis-
sion (40%) and 1 patient showed stable disease (20%) 
throughout treatment (Fig. 2b). 
Association to Other Diseases
Among all patients, metabolic disease including diabe-
tes mellitus, hypercholesterinemia and hypertriglyceride-
mia was present in 10.5% (n = 6), 8.2% (n = 5) and 4.9% 
(n = 3), respectively. Thyroid disease was present in 9.8% 
(n = 6). Infectious diseases were only present in a minor-
ity of patients. Malignant disease was present in 23% (n = 
14) of all patients (Table 3).
First onset
Mean age ± SD (median, range), years
No data, n
Diagnosis 
Mean duration ± SD (median, range), months
No data, n























In this study, we analyzed the baseline characteristics, 
treatment modalities, treatment outcome and the pres-
ence of coexisting diseases in patients suffering from 
GGA treated at our dermatological department within 
the last 20 years.
In our cohort, GGA affected people in the second de-
cade of life, with a female predominance. Female pre-
dominance has been described in GA and may relate to 
molecular events in germline maturation and repair 
[12]. Despite its relative distinct clinical presentation, 
diagnostic delay of 21 months occurred on average, 
which may be attributed to the limited cutaneous symp-
toms and hence limited patient distress. The vast major-
ity of all patients, once diagnosed, received multiple 
lines of treatment. In line with the current literature, po-
tent (e.g., mometasone furoate) to superpotent (e.g., clo-
betasol propionate) topical corticosteroids were also the 
most commonly prescribed treatment modality in our 
cohort, followed by UVA1, potassium iodatum, PUVA, 
UVB, intralesional triamcinolone acetonide and Plaque-
nil [2]. Disappointingly, after 3 lines of treatment, full 
remission was achieved in only 27.9% (n = 17) of all pa-
tients. This emphasizes both treatment resistance and 
lack of causal disease understanding. Of all therapeutic 
modalities applied, a beneficial effect (e.g., full and par-
tial remission) occurred in a majority of patients receiv-
ing UVA1 (45%, n = 9/20), PUVA (63.6%, n = 7/11) and 
intralesional triamcinolone acetonide (100%, n = 5/5). 
Following the most common treatment modality (topi-
cal corticosteroids), only a minority of patients had dis-
ease progression (8.6%, n = 5/58), and most patients had 
stable disease throughout treatment (46.6%, n = 27/58), 
while full and partial remission occurred in only 29.3% 
(n = 17/58). 
First line Second line Third line

















































































































Numerous diseases have been associated with GGA, 
most importantly diabetes mellitus, dyslipidemia, thyroid 
disease, malignancy and infections. Despite initial reports 
on the association of diabetes mellitus and GA, contradic-
tory results with both supporting and refuting data have 
been published [13–16]. In our cohort, diabetes mellitus 
was present in 6 of 57 patients (10.5%). Given the reported 
diabetes mellitus prevalence of 7.4% (±1.1%) in the Swiss 
population within the age group of 55–64 years, one may 
assume that the risk seems to be similar in patients suffer-
ing from GGA [17]. On the other hand, dyslipidemia is by 
now believed to be significantly increased in patients with 
GA, especially in the setting of GGA [4, 18]. Similarly, sev-
eral case reports and case-control studies have revealed a 
higher prevalence of autoimmune thyroid disease in pa-
tients suffering from LGA. In our cohort 9.8% suffered 
from thyroid disease, 9.3% from hypercholesterolemia and 
5.4% from hypertriglyceridemia. It remains unclear wheth-
er this represents an increased prevalence of thyroid dis-
ease or dyslipidemia, given the lack of control cases or data 
on the corresponding disease prevalence. Infectious dis-
eases were present only in a minority of the patients, sup-
porting the current hypothesis that infections may merely 
be an unspecific initiator [19]. Drug-induced GA has been 
reported, and involved medications include biologicals 
(tocilizumab, tumor necrosis factor inhibitors), pegylated 
interferon and amlodipine amongst others [5–7]. Despite 
the resolution of GA upon drug discontinuation, a proof 
of causal relationship does not exist. In our cohort, no 
drug-induced GA was suspected. Given the benign nature 
of GA, when a drug-induced etiology is suspected, discon-
tinuation due to GA should be critically evaluated in the 
context of available and equal alternatives. 
The occurrence of malignant disease at higher rates in 
patients suffering from GGA is controversially debated. 
Case reports have been published on the coexistence of 
malignancy in GGA patients [20–23]. In contrast, a recent 
case-control study did not identify an association of ma-
lignancy in patients suffering from GGA when compared 
to age-matched and sex-matched control patients [24]. In 
our cohort, malignant disease occurred in 23% (n = 14) of 
all patients, including colorectal cancer, lymphoprolifera-
tive disease, squamous cell carcinoma of the esophagus, 
basal cell carcinoma and gynecologic malignancy. 
A limitation of our study is the retrospective, mono-
centric design and the lack of a control cohort. The 
strength of our study is the big cohort size analyzed, con-
sidering the rareness of GGA. Our data contribute to the 
increasing effort in defining appropriate diagnostic pro-
cedures and treatment strategies in this benign, noninfec-
tious granulomatous skin condition. Considering the 
current literature and our cohort data, we suggest to 
screen all patients for dyslipidemia and thyroid disease. 
Furthermore, given the uncertainty of coexistent malig-
nant disease in generalized granuloma and the high rate 
in our cohort, screening (e.g., differential blood count, 
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serum protein electrophoresis, chest X-ray, colonoscopy, 
cutaneous inspection and urological or gynecological ex-
amination) should be considered at a low threshold. Since 
cutaneous manifestations are usually asymptomatic, 
treatment resistant and carry the potential of spontane-
ous resolution, randomized trials are needed in order to 
define optimal treatment strategies. Careful consider-
ation of potential treatment side effects should be empha-
sized. While no treatment may be necessary, we support 
the recommendation of topical corticosteroids as first-
line treatment, given its limited side effect profile and sta-
ble disease control in nearly half the patients in our co-
hort. Single lesions may be additionally treated with in-
tralesional triamcinolone acetonide, though this may not 
be relevant in the setting of widespread disease. If further 
treatment is needed, light therapy (UVA1 or PUVA) may 
represent a good alternative, yet only in patients not at 
increased risk for cutaneous carcinogenesis. Clearly, ran-
domized, placebo-controlled trials are needed, in order to 
define a rational treatment algorithm. Further research is 
crucial in order to elucidate the pathophysiological 
changes underlying GA, which may eventually lead to 
causal treatment strategies. 
Key Message
Treatment resistance is common in generalized granuloma an-
nulare. Concurrent malignant disease should be ruled out.
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